播散性乳腺癌内分泌疗法,应根据肿瘤组织的激素受体水平选择制剂。但有些医院不能测定肿瘤的受体,作者根据临床经验选择内分泌疗法的制剂。治疗广泛性乳腺癌119例,先用雌激素拮抗剂他莫昔芬治疗,口服20mg/12h,治疗3个月,肿瘤退化18例(15.1％),病变稳定83例(69.8％),肿瘤发展18例(15.1％)。停月经10年以上的老年患者疗效较好;对原发灶、皮肤和淋巴结受损害者疗效较好;对肺和胸膜转移者疗效较差。出现不良反应5例 Disseminated breast cancer endocrine therapy should be based on the tumor tissue hormone receptor level selection. However, some hospitals cannot determine the receptors for tumors. The authors selected endocrine therapy preparations based on clinical experience. Treatment of 119 cases of extensive breast cancer, first treated with estrogen antagonist tamoxifen, oral 20mg/12h, treatment for 3 months, tumor regression in 18 cases (15.1%), 83 cases of stable disease (69.8%), tumor development 18 cases (15.1%). Elderly patients with menopause for more than 10 years have good curative effect; patients with primary lesions, skin and lymph nodes are more effective; patients with lung and pleural metastases have poorer efficacy. Adverse reactions occurred in 5 cases